Categories
Cohance Lifesciences Limited — Board Meeting, 12-05-2026: Outcome of Board Meeting
12-05-2026 · 05:37 pm
Cohance Lifesciences Board approved Q4 & FY26 consolidated financial results. FY26 revenue reached ₹2,268.55 Cr, with net profit at ₹179.23 Cr. Leadership has been strengthened, positioning the company for growth in FY27.
No comments yet. Be the first to comment!